Insulin receptor substrate p53/p58 (IRSp53) is involved in cytoskeletal dynamics and is a candidate disease sensor in polyglutamine expansion neurodegeneration. It is widely expressed throughout the body, but its levels are dramatically elevated in forebrain regions. IRSp53 functions as a signal transducing adaptor between activated Rho family GTPases and their effectors. There are four known alternatively spliced isoforms of IRSp53 that vary by the identity of the 3-terminal exon. We report here that there is a fifth alternatively spliced isoform, IRSp53-B, which lacks 40 amino acids abutting the CRIB/SH3 (Cdc42/Rac-interactive binding/Src homology 3)-binding site. We speculate that the novel form has an altered function related to the mechanism of autoinactivation. IRSp53-B has an odd history in the mammalian lineage, which may complicate the use of rodent models to study cytoskeletal reorganization.
Insulin receptor substrate p53/p58 (IRSp53) is involved in cytoskeletal dynamics and is a candidate disease sensor in polyglutamine expansion neurodegeneration. It is widely expressed throughout the body, but its levels are dramatically elevated in forebrain regions. IRSp53 functions as a signal transducing adaptor between activated Rho family GTPases and their effectors. There are four known alternatively spliced isoforms of IRSp53 that vary by the identity of the 3-terminal exon. We report here that there is a fifth alternatively spliced isoform, IRSp53-B, which lacks 40 amino acids abutting the CRIB/SH3 (Cdc42/Rac-interactive binding/Src homology 3)-binding site. We speculate that the novel form has an altered function related to the mechanism of autoinactivation. IRSp53-B has an odd history in the mammalian lineage, which may complicate the use of rodent models to study cytoskeletal reorganization.
Insulin receptor substrate p53/p58 (IRSp53) 1 is a central player in cytoskeletal reorganization and a candidate disease sensor of neurodegenerative polyglutamine (polyQ) expansions. Biochemical studies have shown that IRSp53 interacts with many proteins that fall into two classes. The first class is transmembrane receptors, and the interacting proteins are the insulin receptor (Tyr kinase) (1) and brain-specific angiogenesis inhibitor (G protein-coupled receptor) (2) . Cell culture studies show that hamster IRSp53 is phosphorylated by activated forms of human insulin and insulin receptor-related receptors, as well as by the Drosophila insulin receptor (1) . Rat brain insulin receptors are highly enriched in postsynaptic fractions (3) . In cultured hippocampal neurons, IRSp53 and insulin receptors are co-localized to postsynaptic densities. The functional effects of insulin/ insulin-like growth factor 1-induced phosphorylation of IRSp53 are not known.
The second class of IRSp53-binding proteins is involved in stimulus-mediated actin and microtubule cytoskeletal reorganization (reviewed in Ref. 4) . Those proteins are three Rho family GTPases (Rho, Rac, and cdc42) and three Rho family effectors (mDia, WAVE2, and Mena). Two regions of IRSp53 have been shown to interact with GTPases. Rac binds in the helical domain (somewhere in the N-terminal 229 aa) (5) and cdc42 binds in a partial CRIB domain that is 16 aa downstream of the helical domain (6, 7) . Unbound IRSp53 has an inaccessible SH3 domain. Activated forms of GTPases bind IRSp53 and allow its SH3 domain to bind effectors, resulting in various types of actin filament dynamics. Studies show that, through interactions with IRSp53, Rho activates mDia, Rac activates WAVE2, and cdc42 activates Mena (5, 7, 8) . Thus, IRSp53 is an adaptor that couples activators (Rho GTPases) and effectors (Arp2/3-activators).
IRSp53 also interacts with atrophin-1, a protein of unknown function that causes dentatorubral-pallidoluysian atrophy when its polyQ sequence is expanded (9) . PolyQ expansions in atrophin-1 result in a reduced affinity for IRSp53. A key puzzle regarding polyQ disease is how widely expressed mutant proteins can lead to highly tissue-specific cell death. We showed that IRSp53 and atrophin-1 are coexpressed in some cells, e.g. in medium spiny neurons of the striatum (10) . Furthermore, although IRSp53 mRNA is expressed widely throughout the body, it is very strongly enriched in the forebrain and, to a lesser extent, the cerebellum, tissues that are affected in various types of polyQ neurodegeneration (EST SE23B in Ref. 11) (10). We and others have speculated that the role of IRSp53 in polyQ disease may not be restricted to dentatorubral-pallidoluysian atrophy (9, 10) .
IRSp53 originally was identified as IRSp53/p58, a hamster insulin receptor substrate of 53 and 58 kDa (1) . There is a protein family with the same activity and name, IRS. IRSp53 is not a member of the IRS gene family. The N-terminal half of the protein is an IRSp53-specific domain predicted to be almost purely helical. Although there are yeast homologs of Rho GTPases, of IRSp53 effectors, and of another IRSp53-related adaptor (WIP), there is no compelling yeast homolog of IRSp53. There is one candidate yeast homolog, Hof1p, which has an SH3 domain and a weak match to a small portion of the helical domain, but the most divergent species from mammals that has a clear IRSp53 homolog is Drosophila (this study). Flies have one IRSp53 gene, and humans have two (the second is IRSp53-L).
Four isoforms of human and rat IRSp53 have been characterized by Western blotting analysis (12) . These forms are mediated by alternative splicing of the 3Ј-terminal exon; they have identical sequences for the first 511 aa followed by unique sequences of 9 -41 aa. It is not clear what the functional significance of these alternative forms is. We report here the discovery of a novel alternatively spliced isoform that lacks 40 aa in the CRIB/SH3-binding region. This novel form has a curious history in the mammalian lineage, which may complicate the study of human cytoskeletal reorganization in rodent model systems. The location and biochemical profile of the alternative sequence suggest that it is involved in protein binding. We speculate that the affected domain is involved in the autoinactivation mechanism of IRSp53 function.
MATERIALS AND METHODS
RNA and DNA Studies-Non-human RNA was isolated as poly(A) ϩ RNA (FastTrack, Invitrogen) and made into cDNA (First-Strand, Amersham Biosciences). Human total and poly(A) ϩ RNAs were purchased (CLONTECH). All but three of the human cDNAs were equilibrated by total RNA concentration. The others (thalamus, striatum, and hypothalamus), which were made from poly(A) ϩ RNA, were roughly equilibrated to the former by ␤-actin RT-PCR. The primers distinguish true ␤-actin from pseudogenes HBAL (5Ј to 3Ј; ctttgccgatccgccg) and HBAR (cgccctggtgcctgg). The IRSp53 RT-PCR assay was done with the following primers: MHI.L (tccaagtccaacctggtcat) and MHI.R (gtcacgctcttgcgcac). PCR was performed with Taq polymerase (Amersham Biosciences) as suggested by the manufacturer. The RT-PCR parameters were 94°C for 1 min followed by 43 cycles of 94°C for 5 s, 60°C for 5 s, and 72°C for 1 s. The genomic PCR parameters were almost the same except with 72°C for 30 s. Genomic PCR was also done with a partial substitution of dGTP with 7-Deaza-dGTP. This was done to exclude the possibility that the absence of dog and cow products was due to DNA secondary structure (as opposed to being prohibitively long). For sequencing, PCR products were purified of primers (Prep-A-Gene, Bio-Rad) and sequenced directly (AmpliCycle, Applied Biosystems). The prosimian primate used was Loris tardigradus, and the monkey was Macaca mulatta. PCR experiments were analyzed by agarose electrophoresis; negative images of ethidium bromide-stained gels are shown for improved contrast.
Cloning-IRSp53-A1 and B1 were cloned into pCRII-TOPO (Invitrogen) oriented to allow transcription from the pCRII T7 promoter. Plasmid ATG sequences between the T7 promoter and the insert were eliminated by removing the region between the XbaI site and the cloning site. The IRSp53 sequences correspond to GenBank TM sequences AF390178 (isoform A) and AF390179 (isoform B), except they begin 9 bp upstream of those sequences (5Ј terminus is gcagttgtcGCTT-TCCTCAC; capital letters denote the termini of the GenBank TM sequences). We refer to these clones as pCRII-T7-IRSp53-A1 and -B1. Sequencing was done by a combination of manual isothermal sequencing (Sequenase, dI version, United States Biochemical) and Applied Biosystems automated PCR sequencing (The Scripps Research Institute DNA Facility).
In Vitro Transcription/Translation-We used T7 polymerase/rabbit reticulocyte lysate (TnT T7 Quick, Promega) to do coupled in vitro transcription/translation of our pCRII-T7-IRSp53-A1/B1 clones. This system labels protein by [ The CRIB domain is shown in black, and the SH3-binding site is underlined. The alternative region that is present in IRSp53-A but absent in the B form is shown in red. The overlying bracket marks the smallest sequence shown to bind cdc42 (6) . However, it is not known whether any of the second half of that sequence is necessary for that binding. The SH3 domain is in green. The helical domain is shown with the predicted helices marked in blue (see "Materials and Methods"). The perfectly conserved sequences that link the three major helices are overlined. The WW domain and the alternative C-terminal sequence of isoform 1 are given in dark gray and pink, respectively. next to the labeled translation products (Mark12, Invitrogen). The markers were post-stained with Coomassie Blue, and the gels were dried on paper. Labeled protein was visualized by autoradiography. The log of the marker molecular weights was plotted against the distance migrated, and a best-fitting line was drawn through all the points (R 2 ϭ 0.994). The formula of that line was used to extrapolate the experimental products as 53 and 58 kDa.
Bioinformatics-The DNA and protein sequences were analyzed with the BLAST and PSI-BLAST versions currently available at NCBI (www.ncbi.nlm.nih.gov). DNA and protein data base analysis was done with Release 128.0 of GenBank TM . A protein structural prediction of the helical domain was done using 3D-PSSM, a method for protein fold recognition based on one-and three-dimensional sequence profiles coupled with two-dimensional structure and solvation potential (www. bmm.icnet.uk/ϳ3dpssm/) (13) . The helices shown in Fig. 1 were derived from analysis of residues 1-259 of mouse IRSp53; use of full-length IRSp53-A1 yields almost identical results. Most of the helical position predictions have a score of 9, the highest confidence level possible for this program.
RESULTS AND DISCUSSION
In the process of isolating a reference cDNA sequence of mouse IRSp53 (10), we found a novel isoform (Fig. 1) . We performed RT-PCR with mouse whole brain cDNA using primers near the translational start site and in the 3Ј-untranslated regions of IRSp53-1. We cloned the PCR products and sequenced one clone that is nearly identical to hamster and human IRSp53 but is 120 bp shorter in the middle. We then examined other clones and found that we had isolated two cDNA species of IRSp53, one with and one without the 120-bp segment. The full-length forms of mouse and human IRSp53 are 87% identical (over the entire coding sequence) at the DNA level and 96% identical (over the entire 522 aa) at the amino acid level. It is notable that these genes have evolved independently for 160 million years (they shared a common ancestor approximately 80 million years ago). Considering the fact that the third positions of codons are degenerate, 87% conservation of 1569 bp is highly unusual. This suggests that the third position conservation throughout the length of the transcript is due to RNA secondary structure constraints (presumably involved in RNA stability, localization, or regulation).
We confirmed the existence of these two forms by designing primers that span the alternative 120-bp region and repeating the RT-PCR of mouse whole brain cDNA (Fig. 2) . We observed both cDNA species on agarose gels. Those two products were isolated individually from agarose gels, reamplified, and sequenced directly. The two forms correspond to the two clones we had initially sequenced. As previous studies have referred to one of the 3Ј-terminal alternatively spliced mRNAs as the "short form," we have named the new one the "B form." We reasoned that it is the simplest way of referring to the novel alternative position in combination with the four alternative 3Ј-terminal exons (the forms we cloned are IRSp53-A1 and -B1).
We examined this novel alternative splice by RT-PCR of various mouse tissues ( Fig. 2A) . The levels of IRSp53 mRNA are highly elevated in specific regions of the brain (10, 11), so we focused our analysis on the brain. We find that the two forms are expressed in both the brain and periphery. In each tissue we examined, the levels of the B form are small to moderate fractions of total IRSp53 levels. However, the relative amount of the two species cannot be discerned from these highly saturated PCR experiments. To test for tissue-specific regulation of this alternative splicing phenomenon, we selected cDNAs of apparent low and medium relative IRSp53-B levels and performed a quantitative version of the same assay. Fig.  2B shows that the levels of IRSp53 are highly variable between different tissues, roughly 3% in liver and 30% in whole brain. This finding suggests that we are not studying a stochastic process based on the relative strength of the two alternative splice sites but, rather, a regulated alternative splice.
FIG. 2. Mouse RT-PCR analysis.
A PCR assay spanning the alternatively spliced region was used to amplify IRSp53-A and -B in one reaction with one pair of primers. PCR products were analyzed by agarose electrophoresis; negative images of ethidium bromide-stained gels are shown. A, cDNA from various mouse tissues was assayed for the presence of forms A (262 bp) and B (142 bp). The identity of the larger products is not known, but panel B shows that those products only arise late in the PCR amplification process. B, semiquantitative analysis of two cDNAs from panel A. Liver and brain cDNA was serially diluted 2-fold and amplified as described in A. In the liver, there is ϳ32-fold more A form cDNA than B form, and in brain there is ϳ2-fold more A form. DNA marker sizes are given in bp. m, marker; Ϫ, no template control; br, whole brain; ob, olfactory bulb; cx, cortex; ca, caudate putamen; hy, hypothalamus; cb, cerebellum; li, liver.
FIG. 3. SDS-PAGE analysis of recombinant IRSp53-A and -B.
Mouse IRSp53-A1 and -B1 were cloned downstream of the T7 promoter. Those constructs were used to perform coupled in vitro transcription/ translation with [
35 S]Met. The recombinant products were analyzed by reducing SDS-PAGE along with a "no DNA" control (Ctrl). The protein standards were detected by Coomassie Blue staining. The gel was dried and autoradiographed. Protein standards were used to size the recombinant products. The two products have predicted masses of 58 (IRSp53-A) and 53 (IRSp53-B) kDa.
There is confusion regarding the identity of IRSp53 protein species observed by SDS-PAGE analysis. There are two predominant species seen in various rodent tissues (1, 3) ; one has an apparent mass of 53 kDa and the other of 58 kDa. The molecular bases of the two protein species are not clear. We made protein expression constructs placing the T7 promoter in front of IRSp53-A and -B and performed coupled in vitro transcription/translation. The translation products were analyzed by SDS-PAGE under reducing conditions (Fig. 3) . We found that the two forms have mobilities corresponding to masses of 53 and 58 kDa.
We were able to isolate the corresponding genomic region of the mouse IRSp53 by PCR because the intron flanking the alternative sequence is exceptionally short (Figs. 4 and 5D) . Mapping of the alternatively spliced DNA sequence to the genomic sequence reveals that the alternative sequence is not an independent exon but rather is an extension of the downstream exon. The gene structure of IRSp53 (data not shown) reveals that it is exon 9 that has two alternative 3Ј splice sites. We examined the two mouse splice sites for clues about regulation. There are two mechanisms that would explain the varying ratios of A/B forms: activation of one splice site or blocking of the other. Comparison of the two sites weakly favors the later model. When the consensus matching of 3Ј splice sites is equal, as it is in this case, the strength of splice sites can be attributed to the pyrimidine density of the polypyrimidine (polyPy) tract. We observe that the A splice site has a very strong polyPy tract (Py density of 14/15 or 18/20 bases), and the B splice site has a slightly weaker tract (13/14 or 16/20). The splice site qualities alone would predict an approximately fixed ratio of the two forms, with the A form dominating. That is, the A splice site is very robust, it is stronger than the B site, and it is upstream of the B site. Our finding that the B form may be predominant in some tissues (thalamus, Fig. 5A ) hints that this alternative splicing may be regulated by blocking of the A site.
We isolated the same region of human IRSp53 and looked for the presence of the alternative splice sites (Fig. 3A) . The human A and B consensus-matching splice sites (not including polyPy tracts) are perfectly conserved with those of the mouse, but the relative strengths of the two human polyPy tracts are (Fig. 2 ) was used to assay cDNA and genomic DNA from closely and distantly related mammals. A, RT-PCR of rat tissue cDNAs shows that both the A and B forms are present and at relative levels similar to that seen in mouse. Thalamus appears to be the only tissue we have examined in mouse or rat that has more of the B form than the A form. The abbreviations are the same as in Fig. 2 , with the addition of the following: th, thalamus; po, pons; ki, kidney. B, RT-PCR of human tissue cDNAs reveals only the A form. New abbreviations are: fb, fetal brain; sc, spinal cord; he, heart; fl, fetal liver; lu, lung; sp, spleen; ty, thymus; te, testes; pl, placenta; tr, trachea; ag, adrenal gland; pr, prostate; bm, bone marrow; sm, skeletal muscle. C, RT-PCR of whole brain cDNA from rhesus monkey and cow reveals only the A form. D, PCR of genomic DNA from mouse (mo), rat (ra), dog (do), cow (co), Loris (lo; prosimian primate), and human (hu) reveals that rodents and primates share a small intron size, but dogs and cows do not. more difficult to quantify. The A site polyPy tract appears to be very slightly stronger (A splice site is 14/16 or 17/20 and B is 13/14 or 16/20). However, it should be noted that, unlike the case for most exons, the B splice site and polyPy tract are located in the coding sequence. The mouse/human conservation of DNA sequence in this region could be because of alternative splicing and/or protein sequence conservation. Based on this analysis alone, we would predict the human gene to have the same alternatively spliced B form.
Previous protein studies have shown abundant p53 and p58 forms of IRSp53 in hamsters, rats, and mice (i.e. in rodents) (1, 3) . However, the levels of p53 in pig brain are barely detectable (3). Although there are reports of p53 in humans, it is not precisely clear what the identity and/or SDS-PAGE mobility of this species is (5, 9, 12) . We looked for the novel alternative splice in near and distant mammalian relatives of the mouse, e.g. rats and humans (with approximate divergence times of 10 and 80 million years, respectively). cDNAs from various rat and human tissues were tested with the same RT-PCR assay used with mouse (the primer sequences are conserved in the rodent, bovine, and primate species examined here). The B form is present in rats but not in humans (Fig. 5, A and B) . We increased the levels of human cDNA templates and the PCR cycle numbers to approximately single-molecule detection levels and did not detect IRSp53-B in any human tissue. Cow and monkey whole brain cDNAs were tested and also showed no evidence of IRSp53-B (Fig. 5C) .
It is possible that the eighth intron of rodents is so small that it reduces the splicing efficiency of the A splice site, which would lead to an increased use of the nearest downstream site.
We examined this intron in IRSp53 from other mammals and found that primates and rodents share a small intron size, but that this is not a conserved mammalian feature (Fig. 5D) . Thus, the rodent and primate introns are exceptionally short, and the cow and dog introns appear to be much larger. The size of the eighth intron does not appear to be related to the presence of the alternative B form (i.e. humans have a small intron but no form B). These findings indicate that there may have been accelerated evolution in this IRSp53 gene region in the mammalian lineage.
We studied the IRSp53 protein sequence for clues about function (Fig. 1) . The partial or variant CRIB domain has been characterized functionally (6, 7) , and the SH3-binding domain has been noted previously (14) , but we wish to note two observations. First, the CRIB domain and the SH3-binding site overlap and may represent two functional modes of the same site. Second, although the SH3-binding site has been referred to as a PxxP sequence (i.e. a common sequence), it is a perfect Class I SH3-binding site (N to C terminally, a basic aa followed by two iterations of any aa, a hydrophobic aa, and a Pro (reviewed in Ref. 15) ). Another protein sequence feature that has been described only minimally is the helical domain. The distinguishing characteristic of IRSp53 is its predicted helical domain, but it has never been described beyond that point. The mouse helical domain appears to be primarily composed of three large helices (see "Materials and Methods"). Intriguingly, there is strong sequence conservation in the two short sequences (SQGSK is perfectly conserved) that link the three helices.
A search for divergent homologs of mammalian IRSp53 using On the alignment of all related sequences, fly positions that match non-consensus residues are in gray. The underlined sequence corresponds to the alternatively spliced region that distinguishes form A from B. B, IRSp53 is released from autoinactivation by cdc42 binding in the CRIB/ SH3-binding region (black). GTPase cdc42 (G, yellow) binding frees the SH3 domain (green) for Rho family effector (E, pink) binding, which leads to Arp2/3-mediated cytoskeletal reorganization. We propose that autoinactivation may be mediated by the interaction of the SH3-binding site with the SH3 domain. The IRSp53-A/B alternative region (red) may be part of the CRIB/SH3-binding region. Such an extended SH3-binding region could interact directly with the SH3 domain. Alternatively, that region could be necessary for proper folding of the autoinhibited state of IRSp53 or for interaction with other regulatory proteins. We speculate that in each of these scenarios, the most likely functional consequence is that IRSp53 is at least partially constitutively active.
BLAST analysis yielded a single one, found in Drosophila (CG7624 aa 41-846, GenBank TM AAF50086). We compared it and a protein commonly referred to as the yeast IRSp53 homolog, Hof1p, with the mouse protein. The fly helical domain is 26% identical, 55% similar over 141 aa (with two gaps) to the mammalian domain. The helical region of yeast Hof1p is 26% identical, 48% similar over 75 aa (two gaps) in the same region. However, when that core 75-aa region of mouse IRSp53 (which matches both the yeast and fly candidates) is analyzed with PSI-BLAST against the full nonredundant GenBank TM data base, Drosophila IRSp53 is the only non-chordate match (even after five iterations). The fly SH3 domain sequence is 44% identical, 69% similar to that of the mouse over 58 aa (two gaps). The yeast SH3 domain is 20% identical, 44% similar over 62 aa (two gaps). Finally, we found that Drosophila and mouse IRSp53 share a verprolin domain. 2 The verprolin domain is present only in mammalian isoform 2, establishing it as the ancestor of the four C-terminal alternative forms (it is also present in IRSp53-L). The fact that verprolin domains activate Arp2/3 (reviewed in Ref. 16) suggests that the ancestral form of IRSp53 directly activates Arp2/3 and that the three other mammalian forms require effectors. Based on protein sequence, it is unclear whether Hof1p is a true homolog of mouse IRSp53, but the fly protein does appear to be one.
When we align IRSp53 from Drosophila and mice, the helical, SH3, and verprolin domains align robustly. The next best protein match between fly and mouse IRSp53 corresponds to the CRIB/SH3-binding area (Fig. 6A) . Curiously, the order of the CRIB/SH3-binding site and the SH3 site are reversed in the two species, but the distance between them is the same. The fly site is 90 aa downstream of the SH3 domain, whereas the mammalian site is 90 aa upstream. Protein alignment of the fly site with that of mouse and human IRSp53 and with related sequences, described by Govind et al. (6) , suggest that it is a conserved element (Fig. 6A) . Although the sequence homology extends from the CRIB/SH3-binding site to the alternative exon sequence, three of the six matches in the alternative region are not conserved in humans and mice. This portion could be a spurious match or it could be related to the biology difference between rodents and primates (i.e. as this region of IRSp53 in the two species has different biochemical roles).
There are two features of the novel splice variant that have functional implications. First, the alternative sequence is only 4 aa from the CRIB/SH3-binding site. The alternative form removes 40 aa abutting that functional domain; it is difficult to imagine that this does not have an effect on the structural context and function of the CRIB/SH3-binding site. Second, the alternative 40 aa is 15% Pro and 20% charged residues, hinting that it is a protein-binding region. It could either be part of the CRIB/SH3-binding site or it could interact with other proteins.
CONCLUSIONS
It is widely believed that mammalian proteomes are almost identical and that species variations are mostly due to the regulation of gene expression. Here we report an exception in a highly conserved protein, i.e. protein variation results from regulation of alternative splicing. We observe a novel alternatively spliced form of IRSp53 in rodents but not in cows or primates. It remains to be demonstrated that this form is translated and stable. However, several genetic features suggest that this form is functional: it represents a significant proportion of IRSp53 transcripts, it is highly regulated, and it has evolved unchecked for at least 20 million years of divergence time (in mice and rats). Biochemical considerations are consistent with this possibility and suggest a possible role for the alternative form. It is not yet clear whether the novel form is ancestral and was lost in the human and cow lineages or if it emerged in the rodent lineage.
The novel form is the fifth alternatively spliced isoform of IRSp53. The four other forms represent four different C termini. We have proposed that isoform 2 directly activates Arp2/3, whereas the other forms require intermediary effectors. 2 The new B form is generated by the in-frame elimination of 40 aa. This alternative region is 4 aa downstream of the partial CRIB/SH3-binding site and 45 aa upstream of the SH3 domain. As the full-length protein is 96% identical between humans and mice, the removal of such a large portion of the protein likely has major functional effects. The fact that the alternative 40 aa are 15% Pro and 20% charged residues suggests this region is involved in protein binding. The location of the alternative sequence, abutting the CRIB/SH3-binding site, hints that it may be part of that functional domain.
There is a recurring theme in the activation of various types of Ras superfamily effectors. Although GTPases bind to conserved motifs such as the CRIB domain of Rho-family effectors, it is the flanking sequence that undergoes the structural changes required for effector activation (discussed in Ref. 17) . For example, it has been shown that the critical regulatory region of WASP does not include the N-terminal portion of the CRIB domain, but does include the sequence immediately downstream of this domain (17) . The GTPase-binding domain of WASP mediates autoinactivation by binding the C-terminal VCA region. Activation occurs when a GTPase binds to that site and liberates the VCA. (Although one of the four IRSp53 isoforms (the ancestral isoform present in flies) has a partially conserved VCA region, 2 it lacks the motif that interacts with the GTPase-binding domain.) Both IRSp53 and WASP have a polyproline region immediately downstream of the GTPasebinding domain. It is possible that this CRIB-flanking region of IRSp53 has a function similar to that of WASP.
These considerations lead us to propose the model in Fig. 6B . The overlapping CRIB and SH3-binding sites appear to comprise one functionally integrated unit. It is known that this CRIB domain interacts with cdc42 and that this interaction results in the breaking of the reclusion of its SH3 domain. The cdc42-bound form of IRSp53 is active because its SH3 domain is free to interact with Rho family effectors. One possibility is that autoinactivation is mediated by the SH3-binding site binding to the SH3 domain. (Although this possibility seems obvious, we have not found it stated in the literature.) If this were true, we would expect that biochemistry to be affected by the removal of the large alternative sequence that lies between those two domains. We speculate that IRSp53-B is either constitutively active or that it is regulated by another mechanism (e.g. through the Rac-binding site in the helical domain) (5).
